| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 3 securities · may seek to influence control | ||||||
|
Veradermics, Incorporated
13D/A
MANE · 922967104
|
8.8% |
8/21/2026
Event 8/19/2026
|
||||
| Montanova Capital, LLC | 8.8% | |||||
| Averill Master Fund, Ltd. | 7.4% | |||||
| Averill Madison Master Fund, Ltd. | 1.5% | |||||
| Aaron Cowen | 8.8% | |||||
|
Avalyn Pharma Inc.
13D
AVLN · 05348Y105
|
5.6% |
5/8/2026
Event 5/1/2026
|
||||
| Suvretta Capital Management, LLC | 5.6% | |||||
| Averill Master Fund, Ltd. | 4.9% | |||||
| Averill Madison Master Fund, Ltd. | 0.7% | |||||
| Aaron Cowen | 5.6% | |||||
|
Benitec Biopharma Inc.
13D/A
BNTC · 08205P209
|
44.1% |
11/10/2025
Event 11/7/2025
|
||||
| Suvretta Capital Management, LLC | 44.1% | |||||
| Averill Master Fund, Ltd. | 37.8% | |||||
| Averill Madison Master Fund, Ltd. | 6.3% | |||||
| Aaron Cowen | 44.1% | |||||
| Schedule 13G · 24 securities · passive | ||||||
|
Fulcrum Therapeutics, Inc.
13G/A
FULC · 359616109
|
0% |
11/13/2026
Event 9/30/2026
|
||||
| Montanova Capital, LLC | 0% | |||||
| Averill Master Fund, Ltd. | 0% | |||||
| Aaron Cowen | 0% | |||||
|
Faeth Therapeutics, Inc.
13G/A
FTH · 81728A207
|
8.9% |
11/13/2026
Event 9/30/2026
|
||||
| Montanova Capital, LLC | 8.9% | |||||
| Averill Master Fund, Ltd. | 7.6% | |||||
| Aaron Cowen | 8.9% | |||||
|
Aura Biosciences, Inc.
13G/A
AURA · 05153U107
|
2.9% |
11/13/2026
Event 9/30/2026
|
||||
| Montanova Capital, LLC | 2.9% | |||||
| Averill Master Fund, Ltd. | 2.4% | |||||
| Aaron Cowen | 2.9% | |||||
|
Immatics N.V.
13G/A
IMTX · N44445109
|
5.8% |
11/13/2026
Event 9/30/2026
|
||||
| Montanova Capital, LLC | 5.8% | |||||
| Averill Master Fund, Ltd. | 4.99% | |||||
| Aaron Cowen | 5.8% | |||||
|
Capricor Therapeutics, Inc.
13G/A
CAPR · 14070B309
|
0% |
11/13/2026
Event 9/30/2026
|
||||
| Montanova Capital, LLC | 0% | |||||
| Averill Master Fund, Ltd. | 0% | |||||
| Aaron Cowen | 0% | |||||
|
Abeona Therapeutics Inc.
13G/A
ABEO · 00289Y206
|
0.9% |
8/14/2026
Event 6/30/2026
|
||||
| Montanova Capital, LLC | 0.9% | |||||
| Aaron Cowen | 0.9% | |||||
|
Kura Oncology, Inc.
13G/A
KURA · 50127T109
|
9.7% |
8/14/2026
Event 6/30/2026
|
||||
| Montanova Capital, LLC | 9.7% | |||||
| Averill Master Fund, Ltd. | 8.8% | |||||
| Aaron Cowen | 9.7% | |||||
|
Monte Rosa Therapeutics, Inc.
13G/A
GLUE · 61225M102
|
4.2% |
8/14/2026
Event 6/30/2026
|
||||
| Montanova Capital, LLC | 4.2% | |||||
| Averill Master Fund, Ltd. | 3.8% | |||||
| Aaron Cowen | 4.2% | |||||
|
InflaRx N.V.
13G/A
IFRX · N44821101
|
15.6% |
8/14/2026
Event 6/30/2026
|
||||
| Montanova Capital, LLC | 15.6% | |||||
| Averill Master Fund, Ltd. | 12.5% | |||||
| Aaron Cowen | 15.6% | |||||
|
Replimune Group, Inc.
13G/A
REPL · 76029N106
|
7.9% |
8/6/2026
Event 7/30/2026
|
||||
| Montanova Capital, LLC | 7.9% | |||||
| Averill Master Fund, Ltd. | 6.7% | |||||
| Aaron Cowen | 7.9% | |||||
|
Erasca, Inc.
13G/A
ERAS · 29479A108
|
1.1% |
5/12/2026
Event 3/31/2026
|
||||
| Suvretta Capital Management, LLC | 1.1% | |||||
| Averill Master Fund, Ltd. | 0.9% | |||||
| Aaron Cowen | 1.1% | |||||
|
Zura Bio Limited
13G/A
ZURA · G9TY5A101
|
9.9% |
5/12/2026
Event 3/31/2026
|
||||
| Suvretta Capital Management, LLC | 9.9% | |||||
| Averill Master Fund, Ltd. | 8.8% | |||||
| Aaron Cowen | 9.9% | |||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
7.7% |
4/13/2026
Event 4/6/2026
|
||||
| Suvretta Capital Management, LLC | 7.7% | |||||
| Averill Master Fund, Ltd. | 6.5% | |||||
| Aaron Cowen | 7.7% | |||||
|
Sutro Biopharma, Inc.
13G/A
STRO · 869367102
|
0% |
2/13/2026
Event 12/31/2025
|
||||
| Suvretta Capital Management, LLC | 0% | |||||
| Averill Master Fund, Ltd. | 0% | |||||
| Aaron Cowen | 0% | |||||
|
Biohaven Ltd.
13G/A
BHVN · G1110E107
|
7.8% |
2/13/2026
Event 12/31/2025
|
||||
| Suvretta Capital Management, LLC | 7.8% | |||||
| Averill Master Fund, Ltd. | 6.6% | |||||
| Aaron Cowen | 7.8% | |||||
|
Palvella Therapeutics, Inc.
13G/A
PVLA · 697947109
|
7.4% |
11/13/2025
Event 9/30/2025
|
||||
| Suvretta Capital Management, LLC | 7.4% | |||||
| Averill Master Fund, Ltd. | 6.5% | |||||
| Aaron Cowen | 7.4% | |||||
|
89bio, Inc.
13G/A
ETNB · 282559103
|
5.6% |
11/13/2025
Event 9/30/2025
|
||||
| Suvretta Capital Management, LLC | 5.6% | |||||
| Averill Master Fund, Ltd. | 4.8% | |||||
| Aaron Cowen | 5.6% | |||||
|
Compass Therapeutics, Inc.
13G/A
CMPX · 20454B104
|
8.2% |
8/21/2025
Event 8/13/2025
|
||||
| Suvretta Capital Management, LLC | 8.2% | |||||
| Averill Master Fund, Ltd. | 7.1% | |||||
| Aaron Cowen | 8.2% | |||||
|
PepGen Inc.
13G/A
PEPG · 713317105
|
0.9% |
8/13/2025
Event 6/30/2025
|
||||
| Suvretta Capital Management, LLC | 0.9% | |||||
| Averill Master Fund, Ltd. | 0.9% | |||||
| Aaron Cowen | 0.9% | |||||
|
ArriVent BioPharma, Inc.
13G/A
AVBP · 04272N102
|
9.9% |
8/13/2025
Event 6/30/2025
|
||||
| Suvretta Capital Management, LLC | 9.9% | |||||
| Averill Master Fund, Ltd. | 8.7% | |||||
| Aaron Cowen | 9.9% | |||||
|
Molecular Partners AG
13G
MOLN · 60853G106
|
10.6% |
5/2/2025
Event 6/15/2021
|
||||
| Suvretta Capital Management, LLC | 10.6% | |||||
| Averill Master Fund, Ltd. | 10.6% | |||||
| Aaron Cowen | 10.6% | |||||
|
DBV Technologies S.A.
13G
DBVT · 23306J309
|
9.9% |
4/11/2025
Event 4/7/2025
|
||||
| Suvretta Capital Management, LLC | 9.9% | |||||
| Aaron Cowen | 9.9% | |||||
| Averill Master Fund, Ltd. | 8.8% | |||||
|
Aadi Bioscience, Inc.
13G
WHWK · 00032Q104
|
10.0% |
3/11/2025
Event 3/4/2025
|
||||
| Suvretta Capital Management, LLC | 10.0% | |||||
| Averill Master Fund, Ltd. | 8.9% | |||||
| Cowen Aaron | 10.0% | |||||
|
Marinus Pharmaceuticals, Inc.
13G
MRNS · 56854Q200
|
5.5% |
2/11/2025
Event 2/7/2025
|
||||
| Suvretta Capital Management, LLC | 5.5% | |||||
| Averill Master Fund, Ltd. | 5.5% | |||||
| Aaron Cowen | 5.5% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.